ClinicalTrials.gg
CompletedNCT07700615Updated Jul 14, 2026

Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults

A Phase 4 interventional study of Mexidol and Standard Therapy in Vascular Cognitive Impairment no Dementia, sponsored by Pharmasoft. Completed at 4 sites in Russia. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Pharmasoft · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of Mexidol® sequential parenteral and oral administration as part of comprehensive therapy in older adults with chronic brain ischemia and vascular cognitive impairment, no dementia (VCIND).

Read the detailed description

This is a pilot, open-label, prospective, randomized, comparative, controlled study in parallel groups designed to evaluate the efficacy and safety of sequential Mexidol® therapy used in addition to standard therapy in older adults with chronic brain ischemia and vascular cognitive impairment, no dementia (VCIND).

The study included 120 participants randomized into two groups:

  • Group 1 received standard therapy combined with Mexidol® solution (500 mg once daily, IV infusion) for the first 5 days, followed by Mexidol® FORTE 250 tablets (250 mg three times daily) for 60 days.
  • Group 2 received standard therapy only.

Within each treatment group, a pre-specified subgroup analysis was performed based on the presence or absence of frailty, followed by a comparative analysis of the secondary outcome measures for each subgroup.

02

Conditions studied

  • Vascular Cognitive Impairment no Dementia

Keywords

  • Vascular Cognitive Impairment
  • Pre-Dementia Vascular Cognitive Impairment
  • vascular cognitive impairment no dementia
  • Mild Cognitive Impairment
  • Pre-Dementia
  • VCI
  • MCI
  • Neuroprotection
  • Mexidol
  • Ethylmethylhydroxypyridine Succinate
  • Antioxidants
  • Sequential Therapy
  • Elderly
  • Geriatric Patients
  • VCIND
  • Subgroup Analysis
  • Older Adults
03

In context

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

This study's enrollment of 120 is above the median of 64 across 2,799 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Pharmasoft is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated Form (ICF) by the patient or an impartial witness (in case of physical inability to sign)
  2. Men and women aged ≥ 75 years at the time of signing the ICF
  3. Patients with the diagnosis of mild cognitive disorder / vascular cognitive impairment, no dementia (ICD-10 code F06.7) established at least 1 year prior to screening
  4. A total score of ≤23 points
  5. MRI evidence of vascular brain damage obtained within 1 year prior to screening
  6. Agreement to use highly effective methods of throughout the study and for 3 weeks after study completion. Eligible participants include:

    • women of , who have a negative pregnancy test and use the following contraceptive methods: a barrier method (condom or occlusive cap [diaphragm or cervical/vault cap]) or a double-barrier method (condom or occlusive cap [diaphragm or cervical/vault cap] plus spermicide [foam/gel/film/cream/suppository]); women of non-childbearing potential with documented history of hysterectomy, tubal ligation, infertility, or status for more than 1 year;
    • fertile men who agree to use barrier contraception; men with documented infertility or prior vasectomy.

Exclusion criteria

Exclusion Criteria:

  1. to ethylmethylhydroxypyridine succinate or any other components of the product
  2. Galactose intolerance, lactase deficiency, or glucose-galactose malabsorption
  3. Clinically confirmed dementia, defined with the score of ≤ 24 points and/or a diagnosis of dementia established according to the , Fifth Edition (DSM-5) criteria
  4. Clinical depression, confirmed by a standardized scale score (e.g., Beck Depression Inventory score of ≥ 29 points) or by a psychiatrist's evaluation
  5. Chronic heart failure, class III-IV, according to the (NYHA) Functional Classification at screening
  6. Uncontrolled arterial hypertension
  7. Uncontrolled diabetes mellitus
  8. Thyroid dysfunction: hypothyroidism or hyperthyroidism
  9. Impaired renal function ( calculated by the Cockcroft-Gault formula of less than 50 mL/min) at screening
  10. Impaired hepatic function ( (AST) and/or alanine aminotransferase (ALT) ≥ 2 times the (ULN) and/or total ≥ 1.5 times the ULN) at screening
  11. History of (HIV), syphilis, , and/or
  12. Severe vitamin B12 deficiency (less than 150 pmol/L)
  13. Acute infectious diseases (influenza, upper respiratory tract infections, or other) within 4 weeks prior to screening
  14. Purulent inflammatory diseases of any site
  15. Use of prohibited medications or other substances that, in the investigator's opinion, may interfere with the study results within 30 days prior to screening, or the anticipated need for such medications during the patient's participation in the study
  16. Use of medications based on ethylmethylhydroxypyridine succinate, trimetazidine, cytoflavin, or meldonium within 2 months prior to study initiation
  17. Systemic diseases or connective tissue diseases, requiring prior or current treatment with systemic , cytostatics, or other
  18. History of malignant neoplasms except for patients with no evidence of disease for the past 5 years, completely cured basal cell carcinoma of the skin, or completely cured carcinoma in situ
  19. Other severe, decompensated, or unstable somatic diseases (any diseases or conditions that are life-threatening, worsen the patient's prognosis, or prevent participation in a clinical trial)
  20. Unwillingness or inability of the patient to comply with the Protocol procedures (in the investigator's opinion)
  21. History of and/or current alcoholism, drug addiction, or substance abuse at screening
  22. History of schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorders
  23. Participation in another clinical trial within 3 months prior to study enrollment
  24. Any other conditions that, in the investigator's opinion, preclude the patient's inclusion in the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Mexidol® + Standard Therapy

    Patients receive standard background therapy combined with sequential parenteral and oral administration of Mexidol® for a total duration of 65 days.

    Drug: Mexidol

  • Active comparator
    Standard Therapy Alone

    Patients receive standard background therapy alone.

    Other: Standard Therapy

Interventions

  • In addition to standard therapy, Mexidol sequential therapy was administered in two phases: * Days 1 to 5: Intravenous (IV) infusion of 10 mL (500 mg) once daily, diluted in 100-150 mL of 0.9% sodium chloride solution. Infusion rate: 40-60 drops per minute. * Days 6 to 65: Oral administration of Mexidol® FORTE 250 mg tablets, 1 tablet 3 times daily (750 mg total daily dose) for 60 consecutive days.

  • OtherStandard Therapy

    Standard background therapy administered in accordance with institutional protocols and applicable clinical guidelines, including cognitive training.

06

What researchers measure

Primary outcomes

  1. Change in the Montreal Cognitive Assessment (MoCA) Total Score at Visit 4 compared to Visit 0 by treatment groups

    The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking \[30-point scale: min value 0, max value 30, higher scores mean a better outcome\].

    Time frame: Visit 0 (Baseline, Day -4 to Day 0) and Visit 4 (Day 65±2 days)

Secondary outcomes

  1. Change in the Montreal Cognitive Assessment (MoCA) Total Score at Visit 2 compared to Visit 1

    The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking \[30-point scale: min value 0, max value 30, higher scores mean a better outcome\]. Note: Per protocol, the MoCA assessment is performed at Visit 0 (Screening). For patients where Visit 1 (Randomization) and Visit 0 do not coincide, the screening data are used as the baseline values for Visit 1.

    Time frame: Visit 1 / Visit 0 (Baseline, Day -4 to Day 1) and Visit 2 (Day 5)

  2. Change in the Clinical Global Impression (CGI) Scale Scores at Visit 2 Compared to Visit 1, Including Severity of Illness, Global Clinical Change, and Efficacy Index

    The Clinical Global Impression (CGI) scale is a 3-item observer-rated scale used to evaluate illness severity, global improvement or change, and treatment response. It consists of three independent subscales, each rated separately: CGI-Severity (CGI-S) rates the severity of illness on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); CGI-Improvement (CGI-I) rates the patient's change over time on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse); CGI-Efficacy Index is a 4x4 rating scale that assesses the therapeutic effect and treatment-related adverse events. Scores range from 00 (not assessed) or 01 (marked improvement and no side effects) to 16 (unchanged or worse and side effects outweigh the therapeutic effects). A lower score reflects a better therapeutic index.

    Time frame: Visit 1 (Day 1) and Visit 2 (Day 5)

  3. Change in the Beck Anxiety Inventory (BAI) Total Score at Visit 2 compared to Visit 1

    The Beck Anxiety Inventory (BAI) consists of 21 self-report items (scored on a 4-point scale) used to assess the severity of physical and cognitive anxiety symptoms during the past week. Total scores range from 0 to 63: minimal anxiety (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63). \[Scale range: 0 to 63; lower scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 2 (Day 5)

  4. Change in the Mini-Mental State Examination (MMSE) Total Score at Visit 4 compared to Visit 0

    The Mini-Mental State Examination (MMSE) is a 30-point questionnaire of global cognitive status that assesses five key areas of cognitive function: orientation, registration, attention and calculation, recall, and language. Total scores range from 0 to 30, with higher scores indicating better cognition. A score of 24 or more indicates normal cognition. Scores below 24 indicate cognitive impairment, categorized as mild (19-23 points), moderate (10-18 points), or severe (≤9 points) \[30-point scale: min value 0, max value 30, higher scores mean a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  5. Change in the Lawton Instrumental Activities of Daily Living (IADL) Scale Total Score at Visit 4 compared to Visit 1

    The Lawton Instrumental Activities of Daily Living (IADL) Scale is an 8-item instrument used to assess independent living skills and complex occupational performance. The scale evaluates 8 functional domains: ability to use telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medications, and ability to handle finances. Each item is scored as either 0 (dependent) or 1 (independent). The total score is calculated as the sum of all 8 domains ranging from 0 to 8. A score of 0 represents low functioning (maximum dependence) and a score of 8 represents high functioning (full independence) \[Scale range: 0 to 8; higher scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  6. Change in the Barthel Index (BI) for Activities of Daily Living Total Score at Visit 4 compared to Visit 1

    The Barthel Index (BI) for Activities of Daily Living is a validated 10-item clinician- or caregiver-reported rating scale used to assess a patient's performance and level of independence in basic activities of daily living (ADL) and mobility. The index evaluates 10 functional domains: feeding, bathing, grooming, dressing, bowels, bladder, toilet use, transfers, mobility, and stairs. Items are scored in increments of 5. The total score is calculated as the sum of all 10 items, ranging from 0 to 100. A score of 0 represents complete dependence, while a score of 100 represents complete independence. \[Scale range: 0 to 100; higher scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  7. Change in the Short Physical Performance Battery (SPPB) Total Score at Visit 4 compared to Visit 1

    The Short Physical Performance Battery (SPPB) is a standardized assessment tool used to evaluate lower extremity function and mobility in older adults. It consists of three objective subtests designed to mimic everyday physical demands: a 4-meter walk to assess gait speed, a repeated chair stand test (rising from a seated position 5 times) to assess lower limb strength, and three 10-second static balance tests in different foot positions (side-by-side, semi-tandem, and tandem). Each of the three subtests is scored from 0 to 4, resulting in a total summary score ranging from 0 to 12. Lower scores indicate poorer physical function and higher disability, while higher scores indicate better lower extremity performance and functional independence. \[Scale range: 0 to 12; higher scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  8. Change in the Digit Symbol Substitution Test (DSST) Total Score at Visit 4 compared to Visit 0

    The Digit Symbol Substitution Test (DSST) is used to measure attention, processing speed and executive function. It is a pencil and paper test of psychomotor performance in which the subject is given a key grid of numbers and matching symbols and a test section with numbers and empty boxes. The test consists of filling as many empty boxes as possible with a symbol matching each number. The score is the number of correct number-symbol matches achieved in 90 s. Scores range from 0 to 100, with higher scores indicating higher cognitive function.

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  9. Change in the Multidimensional Fatigue Inventory (MFI-20) Total Score at Visit 4 compared to Visit 1

    The Multidimensional Fatigue Inventory (MFI-20) is a 20-item self-administered questionnaire designed to measure fatigue in five 4-item subscales: General fatigue, Physical fatigue, Reduced activity, Reduced motivation and Mental fatigue. MFI-20 has an even proportion of positively and negatively worded items that are rated on a 5-point Likert scale. Subscale scores (range 4-20) are calculated as the sum of item ratings and a total fatigue score (range 20-100) is calculated as the sum of subscale scores. Higher scores indicate a higher level of fatigue.

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  10. Change in the Beck Anxiety Inventory (BAI) Total Score at Visit 4 compared to Visit 1

    The Beck Anxiety Inventory (BAI) consists of 21 self-report items (scored on a 4-point scale) used to assess the severity of physical and cognitive anxiety symptoms during the past week. Total scores range from 0 to 63: minimal anxiety (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63). \[Scale range: 0 to 63; lower scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  11. Change in the Tinetti Gait and Balance Test Total Score at Visit 4 compared to Visit 1

    The Tinetti Gait and Balance Test is a clinical test for the assessment of balance and gait. It has a gait score and a balance score using a 3-point ordinal scale of 0, 1 and 2. Gait is scored over 12 and balance is scored over 16 totaling 28. The lower the score on the Tinetti test, the higher the risk of falling. Tinetti test score equal or less than 18 shows high risk of fall, 19-23 scores show moderate risk of fall, and score equal or higher than 24 shows low risk of fall. Min value is 0, max value is 28, higher scores mean a better outcome.

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  12. Change in the 36-Item Short Form Survey (SF-36) Total Score at Visit 4 compared to Visit 1

    The 36-Item Short Form Health Survey (SF-36) consists of eight scales yielding two summary measures: physical and mental health. To score the SF-36, scales are standardized with a scoring algorithm or by the SF-36v2 scoring software to obtain a score ranging from 0 to 100. Higher scores indicate a better health status, and a mean score of 50 represents a normative value for all scales. \[Scale range: 0 to 100; higher scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  13. Change in the Clinical Global Impression (CGI) Scale Scores at Visit 4 Compared to Visit 1, Including Severity of Illness, Global Clinical Change, and Efficacy Index

    The Clinical Global Impression (CGI) scale is a 3-item observer-rated scale used to evaluate illness severity, global improvement or change, and treatment response. It consists of three independent subscales, each rated separately: CGI-Severity (CGI-S) rates the severity of illness on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); CGI-Improvement (CGI-I) rates the patient's change over time on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse); CGI-Efficacy Index is a 4x4 rating scale that assesses the therapeutic effect and treatment-related adverse events. Scores range from 00 (not assessed) or 01 (marked improvement and no side effects) to 16 (unchanged or worse and side effects outweigh the therapeutic effects). A lower score reflects a better therapeutic index.

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  14. Change in the Morse Fall Scale (MFS) Total Score at Visit 4 compared to Visit 1

    The Morse Fall Scale (MFS) is a validated 6-item clinician-reported tool used to assess a participant's risk of falling. It evaluates six variables: history of falling, secondary diagnosis, ambulatory aid, intravenous therapy, gait/transferring, and mental status. The total score is calculated as the sum of all items, ranging from 0 to 125. Scores are stratified into low risk (0-24), moderate risk (25-44), and high risk (≥45) of falling. \[Scale range: 0 to 125; higher scores indicate a worse outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  15. Change in the Falls Risk Self-Assessment Scale Total Score at Visit 4 compared to Visit 1

    The Falls Risk Self-Assessment Scale is a 12-item self-administered questionnaire used to evaluate a participant's perceived risk of falling. For each question, a "no" answer is scored as 0 points, while a "yes" answer is scored as either 1 or 2 points, depending on the item weight. The total score is calculated as the sum of all 12 items. Total scores are interpreted as follows: a score of less than 4 points indicates a low risk of falling, and a score of 4 or more points indicates a high risk of falling. \[Scale range: 0 to 14; lower scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  16. Change in the Insomnia Severity Index (ISI) Total Score at Visit 4 compared to Visit 1

    The Insomnia Severity Index (ISI) is a 7-item self-administered instrument used to assess the nature, severity, and impact of sleep disturbances experienced over the past 2 weeks. Individual items are rated on a 5-point Likert scale (0 to 4), with the total score calculated as the sum of all 7 items, ranging from 0 to 28. Total scores are interpreted as follows: no clinically significant insomnia (0-7 points), subthreshold insomnia (8-14 points), clinical insomnia of moderate severity (15-21 points), and severe clinical insomnia (22-28 points). \[Scale range: 0 to 28; lower scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  17. Change in Time to Complete the Trail Making Test Part A (TMT-A) at Visit 4 compared to Visit 1

    The Trail Making Test Part A (TMT-A) is a neuropsychological instrument used to assess visual search, scanning, speed of processing, and executive function. Participants are required to connect a set of 25 encircled numbers in numerical order as rapidly as possible. Performance is scored based on the total time taken to complete the task, where each second equals 1 point. A higher score (longer completion time) indicates cognitive impairment, while a lower score indicates better cognitive performance and faster processing speed. \[Scale range: not applicable; lower scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  18. Change in Time to Complete the Trail Making Test Part B (TMT-B) at Visit 4 compared to Visit 1

    The Trail Making Test Part B (TMT-B) is a neuropsychological instrument used to assess visual search, scanning, speed of processing, cognitive flexibility, and executive function. Participants are required to connect a set of 25 encircled numbers and letters, alternating between numerical and alphabetical order (e.g., 1-A-2-B) as rapidly as possible. Performance is scored based on the total time taken to complete the task, where each second equals 1 point. A higher score (longer completion time) indicates cognitive impairment, while a lower score indicates better cognitive performance. \[Scale range: not applicable; lower scores indicate a better outcome\].

    Time frame: Visit 1 (Day 1) and Visit 4 (Day 65±2 days)

  19. Assessment of Safety

    Total number of adverse events (AEs), stratified by severity and frequency; Incidence of adverse drug reactions (ADRs); Incidence of serious adverse events (SAEs) related to the investigational product; Proportion of participants with at least one reported AE; Proportion of participants who discontinued treatment due to AEs. Note: All clinically significant deviations in patient health status (based on physical examination, laboratory, and instrumental assessments) from baseline screening data and reference ranges were recorded as adverse events. Adverse medical events detected during the screening period were classified as medical history (pre-existing/concomitant conditions).

    Time frame: From Day 1 (Visit 1) to Day 65 (Visit 4)

07

Study locations

4 sites
  • Ivanovo Regional Clinical Hospital
    Ivanovo, 153040, Russia
  • Medinet, LLC
    Saint Petersburg, 197136, Russia
  • City Hospital № 40 of Kurortny District
    Saint Petersburg, 197706, Russia
  • Vsevolozhsk Clinical Interdistrict Hospital
    Vsevolozhsk, 188643, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Nov 2025, 1 month.

Of 51 phase 4 interventional studies under Cognitive Dysfunction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 69. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 14, 2026
StartActual
Sep 14, 2025
Primary completionActual
Nov 5, 2025
CompletionActual
Nov 5, 2025
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07700615
Lead sponsor
Pharmasoft
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Sep 14, 2025
Primary completion
Nov 5, 2025
Completion
Nov 5, 2025
Last update
Jul 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emoxypine succinate

Start the discussion